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Abstract: Over 50 years of cancer therapy history reveals complete clinical responses (CRs) 
from remarkably divergent forms of therapies (eg, chemotherapy, radiotherapy, surgery, 
vaccines, autologous cell transfers, cytokines, monoclonal antibodies) for advanced solid 
malignancies occur with an approximately similar frequency of 5%–10%. This has remained 
frustratingly almost static. However, CRs usually underpin strong durable 5-year patient survival. 
How can this apparent paradox be explained? Over some 20 years, realization that (1) chronic 
inflammation is intricately associated with cancer, and (2) the immune system is delicately 
balanced between responsiveness and tolerance of cancer, provides a greatly significant insight 
into ways cancer might be more effectively treated. In this review, divergent aspects from the 
largely segmented literature and recent conferences are drawn together to provide observations 
revealing some emerging reasoning, in terms of “final common pathways” of cancer cell damage, 
immune stimulation, and auto-vaccination events, ultimately leading to cancer cell destruction. 
Created from this is a unifying overarching concept to explain why multiple approaches to 
cancer therapy can provide complete responses at almost equivalent rates. This “missing” 
aspect provides a reasoned explanation for what has, and is being, increasingly reported in the 
mainstream literature – that inflammatory and immune responses appear intricately associated 
with, if not causative of, complete responses induced by divergent forms of cancer therapy. 
Curiously, whether by chemotherapy, radiation, surgery, or other means, therapy-induced 
cell injury results, leaving inflammation and immune system stimulation as a final common 
denominator across all of these mechanisms of cancer therapy. This aspect has been somewhat 
obscured and has been “lost in translation” to date.
Keywords: chemotherapy, immunotherapy, immune response, common pathways, translational 
research, oscillation, regulatory T-cells, immune modulation, complete responses
Introduction
The low clinical efficacy of therapies for advanced cancer, despite over 40 years of 
intensive funding and research, has been recently noted and commented upon by many 
government authorities and scientific and funding bodies.1–4 This interest is principally 
because of the continually escalating costs associated with clinical cancer care, with 
an aging population in Western countries, and the slow progress in curing cancer.1–4 
Patients with most major advanced cancers can expect a complete response (CR) rate, 
where all cancer disappears, of about 5%–10%, and this has remained frustratingly 
almost static. However, CRs typically underpin durable 5-year survival.5–7
In broad terms, current paradigms in cancer therapy revolve around the capacity of 
chemotherapeutic agents to interfere with cancer cell division, signaling, or cancer cell 
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intracellular metabolism, using chemotherapy, radiotherapy, 
surgery, vaccines, autologous cell transfers, cytokines, 
monoclonal antibodies, and other modalities to cause direct 
cancer cell killing. An apparent divergence in this concept 
has been the antiangiogenic agents, which interrupt tumor 
vasculature and blood supply. However, it has been noted 
for over 100 years that immunological manipulations alone 
can similarly produce some remarkable regressions of cancer, 
apparently quite separately from the standard presumed 
mechanisms of cell death from cytotoxic and antiangiogenic 
agents. Evidence for this derives from reports of seren-
dipitous infection or infective inoculation of cancer patients, 
especially after surgery, from the use of vaccine preparations, 
including bacillus Calmette-Guerin and bacterial extracts; 
or more recently, through cytokines, such as recombinant 
interleukin (IL)-2, and monoclonal antibodies such as the 
anti-cytotoxic T-lymphocyte antigen (anti-CTLA)-4 agents, 
which all possess the capacity to induce cancer regression 
in a clinically indistinguishable manner to that produced by 
standard cytotoxic modalities.
Cytotoxic chemotherapies, radiation therapy, surgical 
resection, vaccine therapies, modified viral agents, laser 
therapy, cryotherapy, radiofrequency ablation, infectious 
agent byproducts, electroporation of antigens, cytokine 
therapies (eg, IL-2, IL-12, interferon [IFN]-α, IFN-γ, tumor 
necrosis factor [TNF]-α), dendritic cell therapies, autolo-
gous cell therapies, natural agents (eg, curcumin, vitamin A, 
vitamin C), and monoclonal antibody therapies are all capable 
of generating a small number of random/unpredictable CRs, 
and when these occur they are frequently associated with 
long-term durable survival.
A paradox seems to exist, because many divergent 
modalities achieve a remarkably similar 5%–10% CR rate. 
How can this be?
Many agents with apparently very widely divergent 
and diverse biological mechanisms of action are capable of 
causing a limited number of random CRs, partial responses, 
and even stability of disease. By drawing observations 
together, it can be reasoned that there is a distinct possibility 
that a “final common pathway” must exist to produce these 
unpredictable CRs. This “final common pathway or mecha-
nism” might likely be operational to collectively explain 
these observations, regardless of the duration and type of 
the initiating therapy.
The realization and consolidation over the last 20 years 
that (1) chronic inflammation is intricately associated with 
cancer, and (2) that there is a delicate constant immune 
system dynamic balance between responsiveness on one 
hand and tolerance of cancer on the other, provides a greatly 
significant insight into the ways cancer might be more effec-
tively and predictably treated.
This review provides some observations from the litera-
ture and recent conferences and proposes some emerging 
reasoning capable of explaining these phenomena in terms 
of a final common pathway(s) of immune stimulation and 
“auto-vaccination events” ultimately leading to cancer cell 
destruction that can produce the CRs and which affect patient 
survival.
Current paradigms are explored relating to mechanism 
of actions of current therapeutic approaches to cancer, some 
important questions are raised, and some considerations are 
proposed that may reasonably offer some unifying explana-
tion for these seemingly disparate observations.
Cancer therapies and mechanisms 
of action
Standard chemotherapy approaches
Standard cytotoxic chemotherapy operates on the well- 
accepted and entrenched paradigm of cytotoxicity towards 
cancer cells during mitotic division and active metabolism. 
Mechanisms for cellular toxicity define different classes of 
agent to include alkylation of DNA (eg, cyclophosphamide, 
chlorambucil, cisplatin, carboplatin, oxaliplatin, melphalan, 
dacarbazine), anti-metabolites (eg, methotrexate, azathioprine, 
mercaptopurine), microtubule spindle poisons (plant 
alkaloids and terpenoids, eg, vinca alkaloids, vincristine, 
vinblastine; podophyllotoxin; taxanes, including docetaxel 
and paclitaxel), topoisomerase inhibitors (eg, type 1 include 
irinotecan and topotecan, and type 2 inhibitors including 
amsacrine, etoposide, etoposide phosphate, and teniposide). 
Cytotoxic antibiotics or antineoplastics (eg, dactinomycin 
[or actinomycin-D], doxorubicin, epirubicin, bleomycin, 
mitomycin-C).5
In many solid cancers, at any one time-point, the propor-
tion of actively dividing cancer cells is estimated to be of the 
order of 20%–40% of the total cell population within the 
tumor mass(es).5 This is because the cells in a malignant mass 
divide asynchronously and haphazardly. This fact means that 
with any one dosing administration the maximum proportion 
of cancer cells that can be influenced by the cytotoxic agent(s) 
is around 30%, leaving some 70% unable to be effected by the 
agent(s). Repeated dosing is assumed to randomly influence 
the remaining cancer cells in the tumor mass when those cells 
commence divisions at later time-points. When a particular 
cancer cell, or clone of cancer cells, can be influenced by the 
cytotoxic agent is currently unpredictable and is determined 
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by probability – defined by a series of mathematical param-
eters, including the timing frequency of the agent’s delivery, 
the half-life of the agent(s), superimposed upon the frequency 
of cell division within the cancer mass(es), the proportion 
of cancer cells actively dividing, and the extent of cancer 
cell killing with each dosing. Vascular injury, especially 
endothelial damage, may compound these parameters and 
enhance cellular killing.
It is also well recognized that cytotoxic agents not only 
affect dividing cancer cells but also kill dividing normal 
cells in a range of tissues, most notably rapidly dividing 
normal cell populations. Nonmalignant cells typically divide 
in a synchronous fashion during clonal expansion to either 
repopulate tissues for replacement of naturally dying or 
injured cells, or in the case of the immune system, in response 
to stimulation from other signals, typically the presence of 
“nonnormal” cellular antigen or inflammatory responses of 
other types; for example, traumatic cellular injury. Rapidly 
dividing normal cells under normal circumstances of clonal 
expansion are particularly vulnerable to injury from exposure 
to cytotoxic agents in the course of cancer therapy. Cells in 
the bone marrow, digestive tract, and hair follicles are often 
affected, directly causing a range of well recognized clinical 
effects such as myelosuppression (both innate and adaptive 
immunosuppression, detected as neutropenia and lym-
phopenia respectively), susceptibility to infection, gastritis 
and diarrhea, mucositis, perforation, and alopecia. Because 
normal, rapidly dividing cells are exquisitely sensitive to 
cytotoxic agents, the consequent side-effects of cytotoxic 
therapy are not uncommonly significant in producing dose 
limitation and cessation, causing either delayed therapy, 
dose reduction, poor compliance, alteration of therapy 
type, complete cessation of therapy, or rarely, early death. 
Exploration of the effects of cytotoxic agents on the bone 
marrow and immune system has yielded some observations 
that are relevant to understanding how chemotherapies may 
actually work. The effects of cytotoxic agents on bone mar-
row are to remove any clonally expanding subpopulations of 
immunological cells. The innate immune response cells are 
particularly sensitive to cytotoxic agents, leading to reduced 
neutrophil and monocyte counts in the circulation and tissues. 
Furthermore, the subpopulations of lymphocytes, both effec-
tor and regulatory arms, including both CD4 and CD8 cells, 
are also highly sensitive to the effects of cytotoxic agents. 
Which cell subpopulations are preferentially killed or affected 
is largely determined by which subpopulations of cells are 
actively/synchronously and discretely dividing and expanding 
at the time of administration of the chemotherapeutic agent. 
The precise nature of the immune system micromanipulation 
that occurs with any one chemotherapy dose is therefore 
largely a consequence of the time that the dose is delivered 
into the patient, the dose size, and the half-life of the agent 
(which determines the duration of effect of the agent). There 
is emerging clinical evidence that the immune system under-
goes dynamic regular homeostatic oscillations in patients 
with advanced cancer, and therefore there is likely a regular 
alternating expansion of the effector arm, followed by the 
regulatory arm, of the immune system that occurs in most, 
if not all, cancer patients.6–9 This means that the timing of 
administration of the chemotherapeutic agent within this 
dynamic framework is also likely to be critical in determining 
not only the side-effects and morbidity, but in determining the 
direction that the immune system is driven – either activation/ 
responsiveness or inhibition/tolerance, and thereby deter-
mining the clinical outcome. This would explain a range 
of common clinical observations that clinicians typically 
see and that are reported in the literature and many studies. 
These include, the random and unpredictable nature of many 
clinical responses, the heterogeneity of observed responses, 
the development of a successful response after previous poor 
responses from repeated dosing, and the variable incidence 
of side-effects, such as neutropenia or lymphopenia (even in 
the same patient with sequential dosing).
Importantly, in addition to cell killing, which is assumed 
to be the main action of most cytotoxic agents, cell injury also 
occurs. Both cell killing and cell injury are associated with 
“danger signals” issued to the immune system, both innate 
and adaptive, which are known to be powerful stimuli and 
drivers of immune reactivity. Therefore, both antigen release 
and danger signals, the two most powerful natural drivers of 
the immune response in evolutionary terms, form an integral 
part of any type of cell damage, lethal or otherwise, induced 
by chemotherapeutic or other means.10
The predictable translation from the often-successful 
mouse experiments to the human situation has been prob-
lematic and disappointing. The sequence of events for suc-
cessful tumor cell inoculation, and the timing of therapy, 
has not yet been accurately addressed. There is a paucity 
of careful time-course studies published that collect serial/
daily blood data over 2–3 weeks or more. Consequently, the 
accurate experimental description of the immune kinetics 
following tumor cell inoculation and the initiation of the 
antitumor immune response, and its subsequent attenuation 
or regulation over time, has not been fully elucidated. Without 
this extended serial data, the finer details of the “bimodal-
ity” issues that precisely influence cancer therapies of most 
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types, including chemotherapy and cytokines, cannot be 
fully observed, appreciated or understood, in either animal 
or human studies.
Radiation therapy approaches
Radiation therapeutic approaches utilize free-radical producing 
effects of ionizing radiation to produce DNA damage and con-
sequent cell death.5 High-energy X-rays gamma-ray emitting 
sources, particles, and electrons are typically used for radiation 
therapy. External beam radiation therapy is the conventional 
form of externally delivered focused X-rays (photons) to a 
localized tumor deposit, often from two separate directions 
to reach the same area. Stereotactic radiation (radiosurgery) 
uses focused external beam radiation therapy to target a well 
defined tumor with a high degree of precision using very fine, 
detailed three-dimensional imaging scans with coordinates 
to plot the area more specifically. It is increasingly being 
used, for example, with lesions deep within the brain. Three-
dimensional conformal radiation therapy is an approach that 
better permits radiation delivery to conform or fit the shape of 
the tumor, reducing the relative toxicity to surrounding normal 
tissues. Intensity-modulated radiation therapy is a modification 
of this, with improved ability to conform the treatment volume 
to concave tumor shapes, like spinal cord or internal organs 
against bone. Brachytherapy is used to place or implant, tem-
porarily or permanently, the radiation emitting source(s) close 
to the cancer mass to release usually, either beta-particles or 
gamma-rays (depending on the source chosen) to cause local 
cancer cell killing. Systemic radioisotope therapy is where 
chemical properties of the isotope itself, such as radioiodine, 
or when chemically linked with another molecule (eg, hormone 
or monoclonal antibody) are capable of more selectively deliv-
ering radioisotopes, usually via ingestion or the bloodstream, 
to a specific organ or tumor site for more selective action. 
Examples are: anti-CD20 monoclonal antibody conjugated to 
yttrium-90, metaiodobenzylguanidine (MIBG) to treat neuro-
blastoma, oral iodine-131 for thyroid cancer, and yttrium-90 
for neuroendocrine tumors. Radioactive microspheres can 
be used to inject selectively into a tumor circulation to radi-
oembolize liver metastases, for example. Particle therapy is a 
form of delivery of high-energy radioactive particles such as 
protons, neutrons, or positive ions to cancer tissues. Electron 
(beam) therapy is generally considered separately, but also 
imparts radiation energy, although with less penetration, and 
is used for more superficial tumors like skin cancer masses 
and breast cancers.5
The common effect of all of the above forms of radiation 
therapy is delivery of high-energy radiation damage to cancer 
cells to cause cellular DNA damage and either activation of 
programmed cell death (apoptosis) or necrosis or cell injury, 
leading to danger signals and antigen release.10 In either 
event, inflammation occurs and immune system activation/
regulation results. Injury to normal dividing cells within the 
path of the radiotherapy beam or from systemic administra-
tion is not uncommon and results in a range of commonly 
observed side-effects of therapy. These include damage 
to epithelial surfaces such as desquamation, burn injury, 
erythema, swelling, local tenderness, ulceration, mucosal 
loss and bleeding, oral ulcers (mucositis), intestinal prob-
lems such as diarrhea and nausea, and immunosuppression. 
Later effects include fibrosis, vascular angiomas, strictures, 
and malignancy.
The radiation is delivered either as a single dose, or more 
commonly, for external forms of radiotherapy, as multiple 
divided fractions over time. With respect to the immune 
system, the intravascular cells circulate through the blood 
vessels in and around the cancer mass(es) and enter the cancer 
interstitium and the surrounding normal tissues, including 
within adjacent lymphoid and bone marrow tissues. These 
leukocytes entering the region are exposed to the direct 
effects of radiation, and the consequent effects of free radical 
formation. In situations where the body region(s) exposed to 
radiation are extensive or if therapy is prolonged, lymphoid 
tissues achieve greater exposure, and the effects on the 
immune system can be appreciable, evidenced by increased 
infection rates. Necrosis caused by radiotherapy can induce 
inflammation at the site(s) of radiation therapy, leading to 
exposure of relatively more immunological cells attracted to 
the area(s), which at the time of exposure, may be actively 
dividing and vulnerable.
Radiation damage to immunological cells can cause 
cell death from apoptosis, and the precise immunological 
cell population influenced will depend on which arm of 
the immune equation (effector or inhibitory) is actively 
expanding/dividing at the time of exposure of the radio-
therapy dose and its toxic byproducts. Therefore, the effects 
of each radiation dose will likely be pivotal upon which 
arm of the immune system is most active at the time of the 
administration. During radiation exposure, if the regulatory 
arm is most active, that will be ablated; alternatively, if the 
effector arm is most active, that will be injured. The balance 
of the extent of the ablation with respect to the overall total 
immune system capacity will therefore largely determine 
the overall damage to the immune system and the precise 
functional effect of each radiation dose or of repetitive effects 
caused by repeated dosing. The effects of radiation on the 
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regional and systemic immune system is, in principle, analo-
gous to the effects of chemotherapy, although potentially not 
as extensive due to the beam exposure, unless large marrow 
areas are included in the radiation field(s). Moreover, radia-
tion damage to cancer cells can induce antigen release and 
can induce a direct anticancer immune response capable of 
driving either activation or tolerance.11–14
Surgical approaches
Surgery is widely assumed to remove cancer by resecting the 
main tumor mass(es), thereby curing the patient. If no cancer 
cells remain, this explanation might be readily acceptable 
in biological terms; however, the literature is increasingly 
recording studies that show that cancer cells circulate intra-
vascularly widely within the body away from the primary 
tumor site, even in early stage cancers. This phenomenon 
has been observed for multiple tumor types, both before and 
after surgery, and is not always clearly associated with an 
adverse prognosis or a more advanced stage of the cancer. 
Moreover, many instances are well-recognized anecdotally 
by practicing surgeons where the cancer is macroscopically 
removed, but residual cancer cells are reported at the margins 
by the pathologist, however in an appreciable number of 
these cases the tumor never regrows at that site. Moreover, in 
reports of resection of multiple metastases, for a range of can-
cers, long-term cure is possible, despite clearly widespread 
hematogenous dissemination of the cancer to multiple body 
sites.15–21 However, the extent of patient survival after surgery 
is highly influenced by disease status and patient selection, 
and is consequently variable. How can these observations be 
explained? Surgery usually aims to remove the cancer in its 
entirety, or at least as a near-entire debulking procedure to 
remove the main cancer mass(es) prior to other therapy. It 
is also well-recognized that surgery is inherently traumatic 
to normal and cancer tissues; indeed, often the aim is to not 
directly visualize cancer tissue at all during surgical extirpa-
tion while resecting a suitable margin of normal surrounding 
tissue(s). Such local tissue trauma is usually quite appreciable 
to anyone who has had surgery, and biologically, causes a 
significant and measurable cascade of cytokine release and 
immune stimulation to occur. Immunosuppression after major 
open surgery is well documented, and usually lasts 7–14 days 
after surgery, unless infection supervenes.5 In general terms, 
during this period, pro-inflammatory cytokines are transiently 
suppressed, and pro-regulatory/inhibitory cytokines are 
elevated. The immune system stimulation that occurs after 
surgery is usually thought of as nonspecific; however, it now 
appears that stimulation of preexisting immune responses 
against the cancer (and other preexisting inflammatory states) 
may well occur to effectively “augment” these ongoing 
immune responses. This boosting of the underlying native 
preexisting immune response(s), may explain why some 
cases of overtly residual cancer after surgery never re-grow 
to produce a “cancer recurrence”. Moreover, cancer antigens 
are released during surgery, especially if the cancer tissue 
is breached or traumatized in some manner, even through 
ischemia. Such an antigen release would effectively consti-
tute an “auto-vaccination” event, with capacity to stimulate 
the immune system in an immediate and prolonged way. 
The direction that the immune response is driven would 
potentially be dependent upon the extent of the stimulation 
from trauma (necrosis and danger signals) and the direction 
that the immune response is pointed – responsiveness or 
tolerance – at the time of surgery.10 This explanation is both 
plausible and supported by some evidence, and if shown to 
be true, then virtually every cancer surgical procedure would 
potentially constitute such a significant “auto-vaccination” 
event, many of which are clinically successful.
Hormonal inhibitors
Initial discoveries that some breast cancers were hormonally 
dependent and that hormonal withdrawal using oophorectomy 
could halt metastatic breast cancer growth for premenopausal 
women were instrumental. Initial observations that admin-
istration of estrogen or progesterone to some women with 
certain breast cancers could stabilize disease progression or 
induce complete cancer regression, while in others could pro-
mote progression, was pivotal for the ultimate development of 
a range of new agents and approaches to therapy for hormone 
sensitive cancers. The discovery that blockade of hormone 
receptors on certain cancer cells could modulate growth 
patterns of these cells both in vitro and in vivo provided a 
massive step forward in so-called hormone sensitive cancers. 
Tamoxifen was the first of the effective specific agents, ini-
tially thought to competitively blockade the estrogen receptor 
(ER) on breast cancer cells. It quickly became apparent that 
not all cancer cells within a cancer mass expressed ER, that 
the intensity of expression varied amongst those cells that did, 
and that some breast cancer cells were apparently responsive 
even if the ER was undetectable in the patient’s cells.5 So that 
heterogenous ER patterns of expression within and between 
tumors was common and that although this helped to deter-
mine responsiveness it was not always clinically predictive. 
The progesterone receptor (PR) expression also appeared to 
play a role, but although this was important, it was not as 
pivotal as ER. Further, aromatase inhibition, using dinitrile 
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(cyanide-like) agents such as anastrozole, exemestane, and 
letrozole, appeared to provide a more complete mode of 
deprivation of sex hormone production through blockade of 
adrenal steroid hormone synthesis, thus removing the actions 
of estrogen and progesterone through the ER and PR on breast 
cancer cells. Another approach, used for premenopausal 
women with breast cancer, is the use of luteinizing hormone 
blockers such as goserelin (Zoladex®;  AstraZeneca, London, 
UK) to prevent ovarian production of sex steroids, analogous 
to surgical oophorectomy.5
Prostate cancer cells are dependent on testosterone for 
adequate growth in many situations and express the androgen 
receptor (AR) heterogeneously within a prostate cancer, and 
with variable intensity, in a similar manner to that seen with 
breast cancer and ER/PR expression. Therefore, removal of 
testosterone stimulation of AR is used for prostate cancer 
therapy to reduce growth rates and in some cases causes 
complete regression.5
The basic methods of androgen deprivation are castration, 
surgical (orchidectomy) or biochemical gonadal testosterone 
depletion (luteinizing hormone-releasing hormone [LHRG] 
agonists, and LHRH antagonists). The extent of testosterone 
blockade from biochemical agents compared with healthy 
males can vary but is often 90%–95%. Estrogen was used 
widely initially to treat prostate cancer, however synthetic 
diethylstilbestrol was associated with serious cardiovascular 
problems. The net effect of estrogen is to block testosterone 
production by the testes by blocking hypothalamic gonado-
trophic hormone release. Anti-androgens produce androgen 
receptor blockade, including within the prostate cancer to 
reduce growth. Combined androgen blockade utilizes both 
castration and anti-androgen agents to ablate testosterone 
and its effects on prostate cancer cells.5
Ovarian cancer cells appear to respond to estrogen and 
progesterone blockade, using tamoxifen and aromatase 
inhibitors in some instances, in a similar fashion to breast 
cancer. This avenue is being actively explored.
The net effects of hormonal blockade are deprivation of 
essential growth signals for cellular survival and expansion. 
Without those essential hormonal influences, the cells 
become quiescent, are damaged, or die. Death is usually by 
apoptosis, but occasionally necrosis occurs. In either case, 
antigenic exposure is produced and the immune system is 
exposed to this tumor antigenic stimulation. The net outcome 
of the exposure to tumor antigen would be expected to be 
determined by whether the immune system was display-
ing the predominant direction of either responsiveness or 
tolerance at the time.
Anti-angiogenic agents  
and vascular inhibitors
Anti-angiogenic molecules act by inhibiting formation of 
endothelium via a variety of approaches. Vascular endothelial 
growth factor (VEGF) inhibitors, such as bevacizumab (Avas-
tin®; Genentech, South San Francisco, CA), are monoclonal 
antibodies which bind to VEGF to prevent activation of the 
VEGF receptor. Other angiogenesis inhibitors, eg, sorafenib 
and sunitinib, bind to surface endothelial cell receptors or to 
downstream signaling pathway proteins to block angiogen-
esis. Bevacizumab has been used for therapy of metastatic 
colorectal cancer, some non-small cell lung cancers, meta-
static renal cell cancer, and glioblastoma.5 It was recently 
withdrawn from approval for use in advanced breast cancer 
due to evaluated inefficacy. Anti-angiogenic agents include 
sorafenib (Nexavar®, Bayer, Leverkusen, Germany), approved 
for hepatocellular carcinoma and kidney cancer, sunitinib and 
everolimus for both renal cancer and neuroendocrine tumors, 
and pazopanib for renal cancer.
Anti-angiogenic agents prevent new vascular formation 
and/or disrupt vascular integrity, and thereby reduce nutri-
tion to the tumor, which can produce effective cancer cell 
killing. They may be combined sequentially or concurrently 
with other chemotherapeutic agents. The net result is cancer 
cell death by either necrosis or apoptosis, leading to antigenic 
release with immune system priming with tumor antigens 
and danger signal release.10 Together, these new agents have 
provided modest and inconsistent improvements in overall 
survival. The effects on the immune system are less clear 
and include injury to lymphoid tissues, including lymph 
nodes, spleen, and bone marrow. The timing of the antigenic 
stimulation of the immune system pathways is potentially 
important, as the direction that the immune system will be 
driven – responsiveness or tolerance – might reasonably be 
expected to depend upon the relative effector versus regula-
tory balance that exists at the time of stimulation.
Metabolic pathway inhibitors  
and monoclonal antibodies
HER-2 (human epidermal growth factor receptor-2; proto-
oncogene Neu, receptor tyrosine-protein kinase erbB-2, 
CD340, or p185) is a surface-bound cell membrane receptor 
tyrosine kinase enzyme encoded by the ERBB-2 human gene, 
with overexpression correlated with higher breast cancer 
aggressiveness in growth and increased disease recurrence. 
HER-2 is normally involved in the signal transduction path-
ways leading to cell growth and differentiation, but in about 
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30% of breast cancers amplification of the HER-2/neu gene or 
overexpression of its protein product occurs.22–25 Overexpres-
sion of HER-2 also occurs in other cancers such as ovarian, 
gastric, esophageal, and uterine (serous endometrial) carci-
nomas. Trastuzumab (Herceptin®; Genentech) is a human-
ized murine monoclonal antibody directed to one part of the 
HER-2 receptor, and its identified mechanisms of action are 
suppression of angiogenesis, cell cycle arrest during the G1 
phase (producing reduced proliferation and cell death), and 
induction of cell killing by immune cells through antibody-
dependent cell-mediated cytotoxicity.25
B-Raf is a member of the Raf kinase family of serine/
threonine-specific protein kinases and is a critical enzyme 
protein for regulation of the mitogen-activated protein kinase 
(MAPK)/extracellular signal-related kinase (ERK) signal-
ing pathway, important for cell division, differentiation, and 
secretory function.26 BRAF gene mutations can be inherited 
or arise later as an acquired oncogene. Malignant melanoma, 
non-Hodgkin lymphoma, colorectal cancer, papillary thyroid 
carcinoma, colorectal cancer, hairy cell leukemia, non-small 
cell lung carcinoma, and lung adenocarcinoma are associ-
ated to variable degrees of different mutations (notably the 
V600E variant).27–31 Over 25 different variant mutations are 
described. B-Raf inhibitors have been described and used 
clinically in trials for therapy for melanoma and other cancers 
overexpressing specific mutations. Examples are PLX4032 
(RG7204; Plexxikon/Hoffmann–La Roche; vemurafenib), 
and GSK2118436 and GSK1120212, and some more general 
B-raf inhibitors including GDC-0879, PLX-4720, and sorafenib 
tosylate. The mechanism of action is thought to be by binding to 
the V600E mutant form of the B-Raf enzyme protein inducing 
programmed cell death. Necrosis of tumor masses has been sug-
gested, and associated antigen and danger signal release would 
be likely.10 There may be a paradoxical stimulation of growth 
through wild-type nonmutant forms of B-Raf. Off-target side 
effects include induction of skin cancers. The overall response 
rate with vemurafenib was 46% and the CR rate was 6%. When 
comparing with non-B-raf selected therapies, these rates should 
logically be halved (ORR 23%, CR 3%).
MEK inhibitors have gained recent interest for cancer 
therapy. MAPKs are serine/threonine-specific protein kinase 
enzymes that catalyze a cascade of intracellular enzymes, the 
MAPK/ERK pathway, in response to a wide range of extracel-
lular stimuli (cellular stress, including osmotic stress, heat 
shock, and pro-inflammatory cytokines and mitogens) for a 
broad range of cellular functions; for example, gene expres-
sion, division and expansion, differentiation, proliferation, 
and cell survival/apoptosis.32 When activated, Ras activates 
RAF kinase,29 which phosphorylates and activates MEK 
(MEK1 and MEK2). MEK activates a MAPK. RAF, MEK, 
and MAPK are all serine/threonine-selective protein kinases. 
Some MEK inhibitors include XL518, CI-1040, PD035901, 
selumetinib, and GSK1120212. MEK inhibitors are currently 
being trialed in combination with B-Raf inhibitors.
The precise mechanisms of action of each inhibitor 
are unclear, despite the site of proposed blockade being 
fundamentally physicochemically understood. The reason 
for this is that the effects upon many groups of normal cells 
in vivo have been incompletely studied to date, including 
those of the immune system. All human cells contain B-Raf, 
C-Raf, MEK, and EGF, usually in wild-type form, although 
it is increasingly being appreciated that mutant forms of all of 
these enzymes are far more widespread than initially thought. 
This means that normal cells are being influenced by these 
agents, which are principally “targeted” at the cancer cells, but 
are accidentally influencing normal cell function in the course 
of cancer therapy, accounting for many of the observed and 
reported “off-target” side-effects of these agents in vivo.
Moreover, the action of these agents on cancer cells is to 
slow growth (although occasionally activation is reported), 
and to cause cancer cell death, with consequent regression 
of cancer masses in some cases. Cell death induces antigenic 
release, immune reactivity, danger signals, and an immune 
response, often with consequent inflammation.10 The direc-
tion and magnitude of this immune response is dependent 
upon the extent of antigen release, the antigenicity of this, 
and likely the balance and direction of the immune response 
at the time of stimulation.
Immunological agents
Cytokines
Cytokines of various types have been used for cancer therapy 
for a number of years and in various combinations with 
other agents. IL-2, initially known as T-cell growth factor, 
has perhaps been the most prominent and sustained agent 
in use for about two decades and still remains in wide use. 
A recent review demonstrated data from multiple studies 
concerning melanoma and renal cell carcinoma and revealed 
an overall CR rate of about 7.6% (from further analysis of 
the reported summarized data).32 IL-2 binds to a trimeric 
receptor complex, which includes the IL-2 receptor alpha 
(CD25), IL-2 receptor beta (CD122), and a common gamma 
chain (γc), which is shared by all members of the family 
of cytokines including IL-4, IL-7, IL-9, IL-15, and IL-21. 
IL-2 receptor (IL2R) complex binding activates the Ras/
MAPK, JAK/Stat and PI 3-kinase/Akt signaling modules 
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in T-cells and several other types of cells. Importantly, and 
a point often overlooked, is that many cytokine receptors, 
like for example IL2R are expressed transiently on T-cells 
over a duration of about 6–8 hours and are then lost from 
the T-cell surface.33–48 It is only during IL2R expression 
that IL-2 can activate the T-cell to induce cell division and 
clonal expansion of T-cells. However, IL2R is expressed on 
both T-effector and T-regulatory cells, and current evidence 
shows that the immune system oscillates in the intensity of 
the inflammatory response in most, if not all, patients with 
advanced cancers. This raises the distinct likelihood that the 
immune system fluctuates in the sequential repetitive cellular 
expansion causing alternate homeostatic activation and then 
inhibition. If this proves indeed to be the case, then T-cells 
from either the T-effector arm or T-regulatory arm of the 
immune response would express and then lose IL2R on their 
surfaces. During transient IL2R expression, either T-effector 
or T-regulatory cells would alternately become responsive 
to IL-2 in the tumor microenvironment. The “bimodal” and 
transient nature of IL2R expression would explain the many 
apparently conflicting observations in the literature for over 
three decades or more, where IL-2 appeared to stimulate 
either a predominantly effector or predominantly regulatory 
immune response, inducing either detectable responsiveness 
or tolerance. Hence, the direction that the immune response 
is driven – overall responsiveness or tolerance – will depend 
on when the IL2R is being expressed, on which cells, and 
whether IL-2 cytokine is present.
Many other cytokines and their receptors are becom-
ing increasingly recognized as possessing “bimodal” and 
transient actions on both T-effector and T-regulatory cell 
populations, capable of inducing either responsiveness or 
tolerance. These now include IFN-γ, IFN-α, TNF-α, anti-
gens of many types, IL-17, IL-12, and recently IL-10.38–46 
Consequently, these “bimodal” attributes are often reported 
as being “paradoxical,” probably because the time domain 
has not yet been accurately mapped using daily/near daily 
data over an extended period (10–21 days or more) to resolve 
the opposing actions over time. Using combined IL-2 and 
CTLA-4, an increased CR rate of 17% with strong durable 
survivals has recently been reported by Rosenberg et al.48
CTLA-4 inhibitors
CTLA-4 (cytotoxic T-lymphocyte antigen 4; CD152) 
is a protein that is a member of the immunoglobulin 
superfamily, which is expressed on the surface of T-effector 
and T-regulatory cells and transmits an inhibitory signal to 
T cells for downregulation of immune responses. CTLA-4 
and the T-cell costimulatory protein CD28 both bind to 
CD80 and CD86 (also called B7) on antigen-presenting cells. 
CTLA-4 induces an inhibitory signal to T cells, whereas 
CD28 provides a stimulatory signal.48–50 T-cell activa-
tion via the T-cell receptor and CD28 leads to increased 
CTLA-4 expression as an inhibitory feedback loop for 
B7 molecules (ie, CD80 and CD86). CTLA-4 gene mutations 
and polymorphisms are associated with insulin-dependent 
diabetes mellitus, Graves’ disease, Hashimoto’s thyroiditis, 
celiac disease, systemic lupus erythematosus, primary biliary 
cirrhosis, multiple sclerosis, and other autoimmune diseases. 
CTLA-4 blocking monoclonal antibodies (eg, ipilimumab 
[MDX-010; Yervoy] and tremelimumab), act by binding to 
parts of the CTLA-4 molecule, thereby blocking the inhibi-
tory signal from CTLA-4 to T-cells, and have been used for 
therapy of malignant melanoma, prostate cancer, and other 
cancers. Overdrive of the immune response with induction of 
autoimmunity can occur, sometimes causing severe adverse 
events, including treatment-associated death. The CR rate for 
patients with advanced melanoma is 1.5%, with an overall 
response rate of 7% and prolongation of survival of about 
10 months before death. As with the IL-2/IL2R circuitry, 
CTLA-4 has “bimodal” expression/activity on effector and 
regulatory T-cell populations.46,47 Recently Qureshi et al has 
suggested CTLA-4 exerts a similar mechanism of expansion 
control on T-effs and T-regs.51 Consequently antibodies (with 
half-lives of 2–3 weeks) targeting CTLA-4 could indiscrimi-
nately blockade either or both T-eff and T-reg populations 
accounting for the unpredictable/random and low number of 
clinical responses seen to date, and explaining the autoim-
mune side-effects.
vaccines
Many vaccine types have been trialed against established 
nonresectable cancers in humans, with variable and limited 
success. However, CRs are well reported in many studies, 
ranging from 2.0%–18.9%.8,48,52–55 Recent interest over the last 
15 years or so has focused on approaches using dendritic cells 
to improve antigen presentation to the immune system both 
systemically and locally within the tumor microenvironment. 
This appeared initially attractive during a time when it was 
strongly held that the problem with anticancer immune 
responses lay significantly with failure of adequate antigen 
presentation to the immune system. Combined accrued results 
from 51 dendritic cell (DC) vaccine studies in almost 1000 
patients were reviewed recently and indicated that the CR 
rates for multiple different DC approaches were between 
2.3% and 3.5%.56 A recent report presents a new insight into 
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antigen stimulation by demonstrating that frequent repetitive 
dosing of vaccine and the persistence over a long duration of 
6 months or more, despite the absence of initially apparent 
clinical effects, may provide important clues towards improv-
ing clinical efficacy.8 This and other reports in the literature 
strongly indicate that antigen presentation per se may not 
be the problem, as the immune system in the cancer patient 
appears to be adequately detecting tumor antigen, but is being 
effectively downregulated to prevent reactivity, resulting in 
tumor tolerance. The fact that CRs can be obtained from vac-
cination alone against cancer (as from cytokines and CTLA-4 
MoAb’s used alone) shows that direct cancer cell killing using 
cytotoxic agents is not necessarily required to achieve strong, 
durable CRs.
Conclusion
Strong durable CRs in human cancers of most types are able 
to be derived by surprisingly diverse presumed and described 
mechanisms of action, and are observed to occur spontane-
ously as well at a low rate without any overt apparent inter-
vention. The effectiveness of the cancer research effort has 
been seriously criticized lately, indicating that small gains in 
disease-free progression of the order of 10 days to 3 months 
are unacceptable, and that “It is just not true . . . how success-
ful the cancer research enterprise is.”4,57 Research approaches 
have evolved into segmented, isolated disconnected efforts 
in highly specific areas of cancer investigation. The indi-
vidual proponents of these therapeutic approaches have put 
forward and propounded individual mechanisms of action; 
for example, actions relying on direct cellular cytotoxicity 
(chemotherapy and radiotherapy), metabolic disjunction or 
suppression (pathway inhibitors), resection (surgery), or 
immunological manipulation (cytokines, CTLA-4 MoAbs, 
vaccines). The observed rates of CR across almost all of 
these approaches of anticancer therapy for advanced human 
cancers (excepting testicular cancer, acute childhood leuke-
mia, choriocarcinoma, and perhaps some lymphomas) are of 
the order of 0%–20% by most methods, averaging at around 
5%–10% overall. Moreover, many approaches regarded as 
current “standard-of-care” therapy have CR rates of well less 
than 10% (eg, lung, melanoma, mesothelioma, pancreatic 
cancers) and very low 5-year survival rates.
Two perhaps surprising points are evident from this 
broad clinical observation: (1) that the similarly uniformly 
low rates of CR are obtained despite a wide and diverse 
range of modalities being used for cancer therapy, and 
(2) that purely immunological therapies can produce CRs 
at approximately the same rates as ablative therapies. These 
points were raised and discussed at several levels at the 
American Society of Clinical Oncology in Chicago, in June 
2011, at the recent Society of Immunotherapy of Cancer 
Conference in Washington DC, November 2011, the NCI 
satellite symposium in November 2011, and also at the 
Australasian Society of Immunology meeting in Adelaide, 
in December 2011.
How can these observations be logically explained? The 
observation that all of the available anticancer therapies, 
apparently regardless of their mechanism of action and 
combination, appear to arrive at a relatively common low 
rate of CR and that this has remained essentially unchanged 
for over 40 years, profoundly suggests that a common final 
biologically limiting pathway may be present to account for 
the above findings. Such a common mechanism for cancer 
control would be an important point to appreciate, and 
would explain our relative lack of progress in understanding 
how to better advance the efficacy of cancer therapy to date. 
That is, to appreciably increase CRs and survival, rather 
than to aim for increasingly marginal improvements with 
complicated and often expensive approaches. Increasing 
the CR rate should be our main goal as espoused recently 
by Tuma.57
What would this common overarching pathway then 
be? It is instructive that for each of the myriad forms of 
cancer therapy – chemotherapy, radiotherapy, surgery, and 
others – there are cancer cells injured or killed as the main 
byproduct of the mechanisms of action. The immune system 
– both innate and adaptive – is designed through evolution 
to detect aberration of the cell membrane. Magnetic reso-
nance spectroscopy studies have demonstrated detectable 
differences in the composition of the cell membrane as the 
cell evolves from normal towards malignancy.58,59 These 
sometimes subtle changes, notably in glycolypids, rather 
than the peptide component where our main focus has 
typically resided, are capable of inducing antigenic profile 
alterations in cells, which the immune system is then capable 
of detecting and reacting towards. Cell damage, both cancer 
and normal, is thereby an important and powerful stimulus 
for tissue inflammatory responses – initially innate, then 
adaptive – with both arms of immunity progressing simul-
taneously after cell danger signals have been liberated.5,8,10 
The immune system is initially stimulated/initiated, and 
then terminated, as a normal homeostatic part of the (acute 
and chronic) inflammatory response, in consort with simul-
taneous hematological, endocrine, and sometimes neural 
responses, as part of the tissue trauma or injury response. 
Pro-inflammatory cytokines and chemokines (which can 
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also be immune suppressive/regulatory) are released upon 
tissue injury, and are more likely to be cancer-directed upon 
cancer cell injury and antigen exposure. With evidence that 
the immune system is already detecting the presence of the 
cancer, as it does with any form of cellular or tissue aberra-
tion, through aberrant glycolipid and other surface markers 
described during (even early) malignant cellular transforma-
tion,58,59 it is clear that the immune system must be respond-
ing, even if in a (subclinical) attenuated manner, to signals 
from (nonnormal) cancer cells. For pure immunostimulant 
agents, such as IL-2, IL-12, or CTLA-4 blocking antibodies, 
to have any effect at all in producing CRs, a preexisting, 
ongoing, immune response against the cancer, with existing 
presentation of tumor antigens, must have been present but 
in a downregulated state. This is supported by knowledge 
that the ineffectiveness of the immune response in patients 
with advanced cancer has been increasingly recognized to be 
associated intimately with the presence of a predominance 
of local and systemic T-regulatory responses.
Additionally, of some importance, is the observation that 
eventually most forms of cancer therapies, regardless of their 
initial proposed mode(s) of action, are later found to have 
some direct action on, or through, the immune system, now 
described with virtually all forms of cancer therapy.
So, if this is true, then why is the immune response driven 
in the correct direction in some cases to induce CRs, but not 
in other cases? The answer to this may likely lie in the recent 
reports of the “bimodality” of action of various and numer-
ous cytokines and chemokines within the human and animal 
immune systems,30–34 and in the “time-dependent” dynamic 
nature of the immune response. An important hint at what is 
likely occurring within our immune systems in cancer is the 
IL-2 and IL2R interaction in a basic acute immune response. 
Antigen is presented; IL2R expression increases initially on 
T-effector cells; these are stimulated by released endogenous 
IL2; IL2R levels then decrease on T-effector cells and are 
lost from their surface; T-effector cells then expand rapidly. 
As part of a feedback response loop some 48-hours later, 
T-regulatory cells commence expression of IL2R on their 
surface; these are then in turn stimulated by released IL2; 
IL2R levels then decrease on T-regulatory cells and are lost 
from their surface; T-regulatory cells then expand rapidly. 
After a refractory delay of some 3–5 days, the cycle repeats 
itself until antigen is removed from the system. If antigen 
is removed completely during the first cycle, an “acute 
immune response” is all that is detected clinically; however, 
if antigen persists – as is inevitably the case with advanced 
nonresectable cancer – the cycle repeats itself continuously as 
a “chronic immune response.” If cancer can be removed, then 
the cycle abates and is damped almost completely; however, 
if cancer remains, then the inflammatory cycle continuously 
attenuates itself to produce a situation of tolerance for the 
aberrant antigen source. This type of repeating inflammatory 
cycle in advanced cancer patients has been documented and 
described now in three clinical laboratories internationally, 
and has been observed to disappear with surgical resection of 
the cancer. Detection of the cycle is dependent on repeated, 
serial, near-daily measurements to define cyclical fluctuations 
in the inflammatory markers. The cycle periodicity appears to 
be about 6–7 days, with certain defined therapeutic windows 
of about 12 hours duration for potential therapeutic effective-
ness.6–9 There appears to be a separate 12-hour window in 
each repeating cycle providing an opportunity for inducing 
activation (responsiveness or stimulation), and another for 
inducing inhibition (tolerance or regulation). If the inflam-
matory stimulus, from cell injury or death for example, is 
generated within the correct critical 12-hour window during 
the approximate 7-day cycle, then the immune response can 
be driven in the desired direction for increased responsiveness 
in order to drive the preexisting already occurring (but weak 
and ineffective) anticancer immune response more strongly 
to overcome problematic coexisting homeostatic regulatory/
inhibitory/tolerogenic responses. These observations and 
points may help answer why multiple forms of apparently 
divergent therapy can damage cancer cells, and in some cases 
effectively enhance existing clinical immune responses to 
induce complete cancer regression, but currently, in a random 
and unpredictable manner.6–9
Summary
Multiple forms of cancer therapy, including pure immuno-
logical therapies, propose widely different mechanisms of 
action for creating CRs and clinical successes. In this review 
and opinion article some of the critical questions that may 
better explain this apparent paradox have been explored. 
Many therapies cause cell damage, cell killing, cancer cell 
antigen release, danger signals, inflammatory activation, and 
immune system stimulation (Figure 1 below).5,10 In this way, 
micromanipulation of the human immune system in patients 
with advanced cancer is extremely likely to be actively occur-
ring with most, if not all, forms of past and current cancer 
therapies in vivo. This effect is evident through direct dam-
age or ablation of immunological cell populations altering 
the relative responsiveness–tolerance balance, and/or from 
the release of tumor antigens from cancer cell injury causing 
enhanced immunostimulation of existing immune responses 
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Figure 1 Multiple cancer therapies leading to a final common pathway of action.
Notes: Many, if not all, cancer therapies lead to cancer cell damage, antigen release, and danger signals, and a final common pathway of immunomodulation, causing in vivo 
responsiveness or tolerance to advanced cancer inducing cancer regression or growth, respectively.
against the cancer. If these points are clarified, treatments 
for cancer might be targeted more specifically for greatly 
improved clinical efficacy in terms of morbidity, CRs, and 
patient survival.
When it is fully appreciated that it is immune system 
micromanipulation that can lead to random CRs, then it is 
highly likely that this can be harnessed for predictable control 
of cancer and chronic inflammation using significant thera-
peutic strategies based on these approaches.6–13
The present authors’ reasoning for a “final common 
pathway” through the human inflammatory and immune 
system offers a quite valid explanation for the observations 
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over time for the random, consistently low number of 
therapeutic successes from multiple, very seemingly 
divergent, forms of cancer therapies. Moreover, the time-
course of therapy with regard to the patient’s own individual 
immune response (requiring frequent regular near-daily 
monitoring to detect) is likely to be a pivotal and critical 
missing factor in determining the direction that the immune 
response will ultimately be driven by therapeutic interven-
tions to achieve control of cancer (and potentially other 
states of chronic inflammation) and to improve the clinical 
outcome. These points have until now, it appears, been 
largely “lost in translation.”
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